Akums Drugs and Pharmaceuticals on Friday reported a 15% rise in adjusted profit to Rs 66.3 crore in the quarter ended Dec. 31, 2024. The company had posted an adjusted profit of Rs 57.5 crore in the same quarter last fiscal, Akums Drugs and Pharmaceuticals said in a regulatory filing.
Adjusted profit is calculated as the profit for the quarter/period plus fair value changes to financial instruments less tax impact on account of business merger, the filing said.
"With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a 200-million-euro contract. The contract involves manufacture and supply of products to be sold in European markets," Sanjeev Jain, Managing Director of Akums Drugs and Pharmaceuticals, said.
Total income of the company during the quarter under review stood at Rs 1,025 crore, as against Rs 1,091 crore in the year-ago period, it added.
Its Managing Director Sandeep Jain said, "We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in third quarter compared to second quarter. We also in-licensed novel products of Triple hair and Caregen in the dermatology and metabolic segment to drive future growth."
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
